Éric Jourdan

3.2k citations

60 papers · 2.1k indexed · 1 hit paper · h-index 22

Impact in

Genetics top 1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research

Papers in ⓘ

Genetics 27
- Myeloproliferative Neoplasms: Diagnosis and Treatment 20
- Chronic Lymphocytic Leukemia Research 6
Hematology 24
- Chronic Myeloid Leukemia Treatments 15
- Acute Myeloid Leukemia Research 7
- Multiple Myeloma Research and Treatments 7

Co-authors: Christos C. Zouboulis (1 shared paper)Mauro Picardo (1 shared paper)Annick Villet (8 shared papers)A. Ravel (8 shared papers)Éric Peyrin (8 shared papers)Catherine Grosset (8 shared papers)Alessandro M. Vannucchi (15 shared papers)Claire Harrison (15 shared papers)
Journals: Blood (12 papers)Journal of Clinical Oncology (7 papers)Journal of the European Academy of Dermatology and Venereology (3 papers)HemaSphere (3 papers)British Journal of Haematology (2 papers)
Partner nations: France United States Italy

In The Last Decade

Éric Jourdan

57 papers receiving 2.1k citations

Hit Papers

align trajectories log scale

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis 2015 · 340 citations

Peers

Countries citing papers authored by Éric Jourdan

Since Specialization

Citations

This map shows the geographic impact of Éric Jourdan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Jourdan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Jourdan more than expected).

Fields of papers citing papers by Éric Jourdan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Jourdan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Jourdan. The network helps show where Éric Jourdan may publish in the future.

Co-authors

The 25 scholars most cited alongside Éric Jourdan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Éric Jourdan Line = papers co-authored together Éric Jourdan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis JAMA Oncology ·Animesh Pardanani, Claire Harrison, Jörge E. Cortes, Francisco Cervantes, Ruben A. Mesa, Donald Milligan, Tamás Masszi, Elena Mishchenko, Éric Jourdan, Alessandro M. Vannucchi, Mark W. Drummond, Mindaugas Jurgutis, Kazimierz Kuliczkowski, Emanuil Gheorghita, Francesco Passamonti, Frank Neumann, Abhay Patki, Guozhi Gao, Ayalew Tefferi Hit paper breakdown →	2015	340
2	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study The Lancet Haematology ·Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Ramón V. Tiu, Pierre Zachée, Éric Jourdan, Elliott F. Winton, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Joanne Lager, Zhenming Shun, Ruben A. Mesa	2017	222
3	Acne is an inflammatory disease and alterations of sebum composition initiate acne lesions Journal of the European Academy of Dermatology and Venereology ·Christos C. Zouboulis, Éric Jourdan, Mauro Picardo	2013	210
4	Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study Journal of Clinical Oncology ·Bertrand Coiffier, Nicolas Mounier, Serge Bologna, Christophe Fermé, Hervé Tilly, Anne Sonet, Christian Bernard, Olivier Casasnovas, Éric Jourdan, Karim Belhadj, Raoul Herbrecht	2003	163
5	A DNA Aptamer as a New Target-Specific Chiral Selector for HPLC Journal of the American Chemical Society ·Mickaël Michaud, Éric Jourdan, Annick Villet, A. Ravel, Catherine Grosset, Éric Peyrin	2003	162
6	Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma Blood ·Karène Mahtouk, Dirk Hose, P Raynaud, Michael Hundemer, Michel Jourdan, Éric Jourdan, Véronique Pantesco, Marion Baudard, John De Vos, Marion Larroque, Thomas Moehler, Jean‐François Rossi, Thierry Rème, Hartmut Goldschmidt, Bernard Klein	2007	116
7	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure American Journal of Hematology ·Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Éric Jourdan, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srđan Verstovšek, Shelonitda Rose, Juan Shen, Tymara Berry, Carrie Brownstein, Ruben A. Mesa	2020	104
8	Immobilized DNA Aptamers as Target-Specific Chiral Stationary Phases for Resolution of Nucleoside and Amino Acid Derivative Enantiomers Analytical Chemistry ·Mickaël Michaud, Éric Jourdan, Corinne Ravelet, Annick Villet, A. Ravel, Catherine Grosset, Éric Peyrin	2004	101
9	APRIL and TACI interact with syndecan‐1 on the surface of multiple myeloma cells to form an essential survival loop European Journal Of Haematology ·Jérôme Moreaux, Anne‐Catherine Sprynski, Stacey R. Dillon, Karène Mahtouk, Michel Jourdan, A. Ythier, Philippe Le Moine, Nicolas Robert, Éric Jourdan, Jean François Rossi, Bernard Klein	2009	89
10	Sensitive skin in France: a study on prevalence, relationship with age and skin type and impact on quality of life Journal of the European Academy of Dermatology and Venereology ·L. Misery, Éric Jourdan, F. Huet, E. Brenaut, B. Cadars, Sandrine Virassamynaïk, Michèle Sayag, C. Taïeb	2018	48
11	Zinc resistance impairs sensitivity to oxidative stress in hela cells: protection through metallothioneins expression Free Radical Biology and Medicine ·Fabrice Chimienti, Éric Jourdan, Alain Favier, Michel Sève	2001	47
12	Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis British Journal of Haematology ·Animesh Pardanani, Ayalew Tefferi, Tamás Masszi, Elena Mishchenko, Mark W. Drummond, Éric Jourdan, Alessandro M. Vannucchi, Mindaugas Jurgutis, Vincent Ribrag, Alessandro Rambaldi, Liang Piu Koh, Shelonitda Rose, Jun Zhang, Claire Harrison	2021	40
13	Phase II study of gemcitabine–dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma Annals of Oncology ·Franck Morschhauser, Stéphane Depil, Éric Jourdan, Marc Wetterwald, Réda Bouabdallah, Gérald Marit, Philippe Solal‐Céligny, Catherine Sebban, Bertrand Coiffier, Nadia Chouaki, F Bauters, Charles Dumontet	2006	34
14	Unexpected high incidence of intracranial subdural haematoma during intensive chemotherapy for acute myeloid leukaemia with a monoblastic component British Journal of Haematology ·Éric Jourdan, Hervé Dombret, Sylvie Glaisner, J M Miclea, Sylvie Castaigné, L Degos	1995	32
15	Nested High-Resolution Melting Curve Analysis Journal of Molecular Diagnostics ·Serge Carillo, Laurent Henry, Éric Lippert, François Girodon, Isabelle Guiraud, C. Richard, Frédérique Dubois Galopin, Cédric Cleyrat, Éric Jourdan, Róbert Královics, Sylvie Hermouet, Thierry Lavabre‐Bertrand	2011	28
16	Study of tryptophan enantiomer binding to a teicoplanin-based stationary phase using the perturbation technique Journal of Chromatography A ·B. Loukili, Christelle Dufresne, Éric Jourdan, Catherine Grosset, A. Ravel, Annick Villet, Éric Peyrin	2003	28
17	Vancomycin Dimerization and Chiral Recognition Studied by High-Performance Liquid Chromatography Analytical Chemistry ·Inès Slama, Christelle Dufresne, Éric Jourdan, Fahrat, Annick Villet, A. Ravel, Catherine Grosset, Éric Peyrin	2002	28
18	Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF). Journal of Clinical Oncology ·Ruben A. Mesa, Miklós Egyed, Anita Szőke, Aleksandr Suvorov, Andrew C. Perkins, Jiřı́ Mayer, Peter Ganly, Éric Jourdan, Harry C. Schouten, Patrizia Tosi, Charles M. Farber, Pierre Zachée, Christof Scheid, James P. Dean, Paul Cernohous, Jyoti Nangalia, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Adam J. Mead, Claire Harrison	2015	27
19	Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF) Blood ·Animesh Pardanani, Claire Harrison, Jörge E. Cortes, Francisco Cervantes, Ruben A. Mesa, Donald Milligan, Tamás Masszi, Elena Mishchenko, Éric Jourdan, Alessandro M. Vannucchi, Mark W. Drummond, Mindaugas Jurgutis, Kazimierz Kuliczkowski, Emanuil Gheorghita, Francesco Passamonti, Frank Neumann, Guozhi Gao, Ayalew Tefferi	2013	27
20	Effects of cadmium and zinc on solar-simulated light-irradiated cells: potential role of zinc-metallothionein in zinc-induced genoprotection Archives of Biochemistry and Biophysics ·Éric Jourdan, Nathalie Emonet‐Piccardi, Christine Didier, Jean‐Claude Béani, Alain Favier, Marie‐Jeanne Richard	2002	26

About Éric Jourdan

Éric Jourdan is a scholar working on Genetics, Hematology, Dermatology, Pathology and Forensic Medicine and Rheumatology, having authored 60 papers that have together received 2.1k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers), Chronic Myeloid Leukemia Treatments (15 papers), Lymphoma Diagnosis and Treatment (9 papers), Acute Myeloid Leukemia Research (7 papers), Multiple Myeloma Research and Treatments (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Eosinophilic Disorders and Syndromes (6 papers) and Analytical Chemistry and Chromatography (5 papers). The work is most often cited by research in Genetics (805 citations), Hematology (703 citations), Dermatology (310 citations), Rheumatology (311 citations) and Molecular Biology (956 citations). Éric Jourdan has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Christos C. Zouboulis, Mauro Picardo, Annick Villet, A. Ravel, Éric Peyrin, Catherine Grosset, Alessandro M. Vannucchi, Claire Harrison, Ruben A. Mesa and Francesco Passamonti. Their work appears in journals such as Blood, Journal of Clinical Oncology, Journal of the European Academy of Dermatology and Venereology, HemaSphere and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact